CISCER® Methylation Test Receives Five Oral Presentations at EUROGIN 2026
The 2026 European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Congress will be held from March 18 to 21 in Vienna, Austria. CISPOLY's cervical cancer methylation detection product "CISCER®" (PAX1/JAM3), based on post-market, clinician-led real-world study results, will be featured in five major oral presentations at the congress, showcasing to the world the breakthrough value of this Chinese innovative technology in real clinical practice.
1. Clinician-Driven Validation, Defining Precision Application Scenarios
CISPOLY's core product CISCER® (Human PAX1/JAM3 Gene Methylation Detection Kit) received NMPA Class III medical device registration in March 2023. Post-market, the company collaborated with clinical experts to actively apply and accumulate data within real clinical pathways, guided by physicians based on specific clinical needs (e.g., HPV-positive triage, cytology ASC-US/LSIL triage). This "physician-led, scenario-validated" approach not only confirmed the high performance of CISCER® testing but also clarified its unique advantages from a clinical perspective in avoiding overtreatment, enabling individualized management, and preserving female fertility, reshaping cervical cancer screening practice.
2. Five International Presentations, Comprehensive Demonstration of Clinical Value
The five presentations at the EUROGIN Congress will systematically showcase the above research findings, covering multiple core sessions:
-
HPV-positive triage management session: Elaborating on how it serves as a highly efficient triage tool to optimize management pathways.
-
Self-sampling session: Demonstrating its robust performance with self-collected samples, advancing screening accessibility.
-
Screening methodology session: Exploring its value as a novel biomarker in overall screening strategies.
-
Methylation session: In-depth sharing of technical principles, clinical data, and Chinese application insights.
3. Rooted in Chinese Innovation, Contributing Global Solutions
Leveraging fully proprietary intellectual property in methylation detection technology, CISPOLY has built a gynecologic tumor early diagnosis product line covering cervical cancer, endometrial cancer (CISENDO®), and ovarian cancer (CISOVA®). This dense presence at EUROGIN — a top international academic platform — signifies that the methylation application solutions jointly explored by Chinese clinical and industry partners have received high recognition from the international academic community, exemplifying the success of Chinese medical device innovation guided by "clinical value orientation."
CISPOLY stated that it will continue to deepen clinical collaborations, expand the application of methylation and other technologies in women's health, and is committed to providing more precise and convenient diagnostic solutions for the world.
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology enterprise driven by innovative science and focused on health. CISPOLY is a pioneer in the field of early diagnosis of gynecologic tumors. With proprietary technology and patent-protected biomarkers at its core, the company has developed early diagnostic products for cervical cancer, endometrial cancer, ovarian cancer, and other gynecologic tumors, filling a void in this field.
As women pay increasing attention to their own health, the women's health market holds great promise. Beyond its gynecologic tumor early screening and diagnosis product line, CISPOLY will continue to build additional women's health-related product pipelines, striving to become a technology-innovation-driven leader in the women's health market.